| Drug General Information |
| Drug ID |
D0R2NE
|
| Former ID |
DCL000795
|
| Drug Name |
Entacapone+levodopa+carbidopa
|
| Indication |
Parkinson's disease; Restless legs syndrome [ICD9: 332, 333.94; ICD10:F02.3, G20, G25.8]
|
Phase 3 |
[1]
|
|---|
| Company |
Orion; Novartis
|
| CAS Number |
CAS 130929-57-6 + 59-92-7
|
| SuperDrug ATC ID |
N04BX02
|
| SuperDrug CAS ID |
cas=116314671
|
| Target and Pathway |
| Target(s) |
Catechol-O-methyl-transferase |
Target Info |
Inhibitor |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Agonist |
[2]
|
|
BioCyc Pathway
|
L-dopa degradation
|
|
Dopamine degradation
|
|
Noradrenaline and adrenaline degradation
|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Tyrosine metabolism
|
|
Metabolic pathways
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Tyrosine Metabolism
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Methylation Pathways
|
|
Metapathway biotransformation
|
|
Estrogen metabolism
|
|
Biogenic Amine Synthesis
|
|
Dopamine metabolism
|
|
Phase II conjugation
|
|
Neurotransmitter Clearance In The Synaptic CleftWP666:Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat. 2008 February; 4(1): 39-47. |
|---|
| REF 2 | Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. |
|---|
